BREAKING
Delta Air Lines March 2026 Quarter Financial Review 20 minutes ago Nurix Therapeutics, Inc. (NRIX) Posts Q1 2026 Results 36 minutes ago RPM International Inc. (RPM) Posts Q3 2026 Results 45 minutes ago Delta Air Lines (DAL) Q1 2026 Earnings: Key financials and quarterly highlights 1 hour ago Academy Sports and Outdoors Drops 6.0% Amid Sector-Wide Selling 22 hours ago Rh Shares Dropping 5.9% 22 hours ago UnitedHealth Group Incorporated Shares Jumping 8.1% 22 hours ago Synergy CHC Corp. (SNYR) Q4 Earnings: Misses on EPS, Revenue Recap 6 days ago Lindsay Corporation Q2: Revenue Slips to $157.7M 6 days ago Kaiser Aluminum Corporation (KALU) Jumps 7.1% to $129.05 6 days ago Delta Air Lines March 2026 Quarter Financial Review 20 minutes ago Nurix Therapeutics, Inc. (NRIX) Posts Q1 2026 Results 36 minutes ago RPM International Inc. (RPM) Posts Q3 2026 Results 45 minutes ago Delta Air Lines (DAL) Q1 2026 Earnings: Key financials and quarterly highlights 1 hour ago Academy Sports and Outdoors Drops 6.0% Amid Sector-Wide Selling 22 hours ago Rh Shares Dropping 5.9% 22 hours ago UnitedHealth Group Incorporated Shares Jumping 8.1% 22 hours ago Synergy CHC Corp. (SNYR) Q4 Earnings: Misses on EPS, Revenue Recap 6 days ago Lindsay Corporation Q2: Revenue Slips to $157.7M 6 days ago Kaiser Aluminum Corporation (KALU) Jumps 7.1% to $129.05 6 days ago
ADVERTISEMENT
Breaking News

CRDO Stock Plunges 10.4% to $104.73 as Three Analysts Slash Price Targets After Earnings

CRDO shares dropped 10.4% to $104.73 as three analysts cut price targets following recent quarterly results, with volume 43% above average.

March 17, 2026 2 min read
salesforce

CRDO shares dropped 10.4% to $104.73 as three analysts cut price targets following recent quarterly results, with volume 43% above average.

Stock Price
$104.72
current
Change
-10.41%
today
Volume
9.6M
shares traded

Analyst downgrades trigger the selloff. Credo Technology Group Holding shares fell 10.4% to $104.73 on March 17, erasing $2.24 billion in market capitalization. The technology stock closed at its lowest level since early February as three Wall Street firms slashed price targets following the company’s recent quarterly results.

Price target cuts reflect tempered expectations. Susquehanna reduced its target to $170 from $230 while maintaining a Positive rating on March 3. Mizuho lowered its Outperform-rated target to $200 from $225, and Rosenblatt cut its Neutral target to $125 from $170. The downgrades came after Credo reported Q3 2026 revenue of $407.0 million, a sequential jump from $268.0 million in Q2 2026, though analysts appear concerned about sustainability of the growth trajectory.

Volume confirms institutional repositioning. Trading volume reached 9.57 million shares, 43% above the 30-day average of 6.70 million. The elevated activity suggests institutional investors are reassessing positions following the analyst actions, with the stock now trading well below the Street’s revised consensus targets.

What to Watch: The next quarterly earnings report will be critical to validate whether the Q3 revenue surge represents sustainable momentum or a one-time spike. With the stock now trading at $104.73 against price targets ranging from $125 to $200, execution in the coming quarter will determine whether analysts revise targets further or restore confidence in the growth story.

This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.

ADVERTISEMENT
Tags: #CRDO